These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21987238)

  • 1. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileishmanial activity of 1,3,4-thiadiazolium-2-aminide in mice infected with Leishmania amazonensis.
    Rodrigues RF; Charret KS; da Silva EF; Echevarria A; Amaral VF; Leon LL; Canto-Cavalheiro MM
    Antimicrob Agents Chemother; 2009 Feb; 53(2):839-42. PubMed ID: 19015338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
    Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM
    Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
    dos Santos AO; Costa MA; Ueda-Nakamura T; Dias-Filho BP; da Veiga-Júnior VF; de Souza Lima MM; Nakamura CV
    Exp Parasitol; 2011 Oct; 129(2):145-51. PubMed ID: 21771592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
    Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study.
    Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
    Biomed Pharmacother; 2007; 61(2-3):148-53. PubMed ID: 17254746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the intralesional treatment with Chenopodium ambrosioides in the murine infection by Leishmania amazonensis.
    Patrício FJ; Costa GC; Pereira PV; Aragão-Filho WC; Sousa SM; Frazão JB; Pereira WS; Maciel MC; Silva LA; Amaral FM; Rebêlo JM; Guerra RN; Ribeiro MN; Nascimento FR
    J Ethnopharmacol; 2008 Jan; 115(2):313-9. PubMed ID: 18035510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of IFN-gamma in experimental Leishmania infantum murine visceral leishmaniasis.
    Garin YJ; Sulahian A; Gangneux JP; Derouin F
    Pathol Biol (Paris); 1997 Jan; 45(1):48-51. PubMed ID: 9097846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immunomodulatory function of 1,3,4-thiadiazole derivatives with leishmanicidal activity.
    Pourrajab F; Forouzannia SK; Tabatabaee SA
    J Antimicrob Chemother; 2012 Aug; 67(8):1968-78. PubMed ID: 22581907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A; Janjua SA; Hussain I
    Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations.
    Delgado G; Sánchez Y; Plaza D; Mariño A; Granados D
    Biomed Pharmacother; 2011 Dec; 65(8):569-77. PubMed ID: 21733656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.